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Abstract
Introduction Due to the complexity of biologics and the inherent challenges for manufacturing, it is important to know the 
specific brand name and batch number of suspected biologics in adverse drug reaction (ADR) reports.
Objective The aim of this study was to assess the extent to which biologics are traceable by brand name and batch number 
in UK hospital practice and in ADRs reported by patients and healthcare professionals.
Methods We performed an online hospital pharmacist survey to capture information on how specific product details are 
recorded during the processes of prescribing, dispensing and administration of biologics in routine UK hospital practice. 
We also assessed the proportion of ADR reports specifying brand name and batch number from electronic ADR reports 
submitted to the UK national spontaneous reporting database, the Yellow Card Scheme, between 1 January 2009 and 30 
September 2017.
Results Brand name recording in routine hospital processes ranged from 79 to 91%, whereas batch numbers were less rou-
tinely recorded, ranging from 38 to 58%. Paper-based recording of product details was more commonly used for recording 
information. A total of 6108 electronic ADR reports were submitted to the Yellow Card Scheme for recombinant biologics, 
of which 38% and 15%, respectively, had an identifiable brand name and batch numbers. Whereas batch number traceability 
in electronic ADR reports improved slightly after the implementation of the European Union pharmacovigilance legislation 
in 2012, no improvement of brand name traceability was observed.
Conclusion Brand name and batch number traceability for biologics in UK ADR reports are generally low. Shortcomings in 
the systematic recording of product details in UK clinical practice may contribute to the limited traceability.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 4-019-00891 -6) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Biological medical products (‘biologics’) are derived from 
living cells or organisms. Due to their inherent complexity 
and challenging manufacturing processes, a degree of minor 
variability may exist between different batches of the same 
product [1–3]. In addition, due to this variability, minor dif-
ferences may occur between original biologic and follow-on 
versions, so-called biosimilars [4]. Manufacturing variability 
has resulted in manufacturing source (product- or batch-)-
specific adverse drug reactions (ADRs) [2, 5]. Thus, when 
ADRs occur, it is important to know the specific product 
name (i.e. brand name) and batch number of the biologic 
involved in order to detect potential manufacturing-related 
safety issues in a timely manner. In order to do so, appropri-
ate systems must be in place to ensure that these details are 
retrievable in the clinical setting and that they are specified 
within any ADR report submitted to regulatory authorities 
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Key Points 
Brand name recording for biologics is high in UK hospi-
tal practice, while batch numbers are recorded to a lesser 
extent.
Brand name and batch number identification is generally 
low for biologics in UK adverse drug reaction reports, 
with only minor improvement over time observed for 
identifiable batch numbers.
Pharmacovigilance legislation has not resulted in a sig-
nificant improvement in the traceability of biologics in 
the UK, and may benefit from improvements of record-
ing and tracing product details throughout the entire 
supply chain in combination with educational activities 
on the importance of traceability for biologics.
UK BIOlogical-TRAraceability in Clinical practice (BIO-
TRAC) study) was to assess the extent to which biologics 
are traceable within the UK hospital setting with regard to 
brand name and batch number identification and spontane-
ous ADR reporting in routine clinical practice. The use of 
recent data also allowed for an assessment of the impact of 
the EU pharmacovigilance legislation on the traceability of 
biologics in the UK. The results of this study should inform 
both national and European policy discussions.
2  Methods
2.1  Data Sources
Data from two sources were evaluated: (1) an online hos-
pital pharmacist survey; and (2) data from electronic ADR 
reports submitted to the UK national spontaneous reporting 
database, the Yellow Card Scheme.
The survey was set up for hospital pharmacists working in 
National Health Service (NHS) hospitals in England, as they 
represent the most central source of information in the hos-
pital setting. In England, publicly funded healthcare is man-
aged and delivered at a local level by NHS trusts. For the 
purposes of the survey, only secondary care hospital trusts 
were included as other types of specialised trusts, such as 
mental health or community health trusts, may not have their 
own pharmacy service and are less likely to use biologics. 
Also, the survey was conducted only within English hospi-
tals in order to minimise the time required to obtain research 
approvals. After excluding community and mental health 
trusts, a total of 174 NHS hospital trusts in England were 
considered eligible for this study and invited to take part in 
the survey. More than one pharmacist was allowed to partici-
pate per NHS trust if they represent different hospital sites or 
specialties within one hospital site. Pharmacists completed 
the survey via a secure web platform hosted by the local 
project partner, the Drug Safety Research Unit (DSRU).
The survey comprised a series of questions on the record-
ing of brand names and batch numbers during the prescrib-
ing, dispensing and administration of biologics in the hos-
pital inpatient setting and in outpatient infusion centres (see 
Electronic Supplementary Material 1). In addition, pharma-
cists were asked for their views on the current bottlenecks 
and potential solutions for improving the traceability of bio-
logics. The study was approved by the NHS Health Research 
Authority and the UK National Institute for Health Research 
Clinical Research Network (NIHR CRN) provided support 
in recruiting NHS hospitals and pharmacists.
Anonymised data were analysed from electronic ADR 
reports submitted directly by patients or healthcare profes-
sionals to the UK Yellow Card Scheme between 1 January 
2009 and 30 September 2017. ADR reports with a suspected 
or marketing authorisation holders (MAHs). In the UK, this 
is stipulated in European Union (EU) legislation via Direc-
tive 2010/84/EU, which was implemented into national law 
in August 2012 [6, 7].
Several studies have concluded that specific product 
details are not always included in ADR reports, in particular 
when it comes to batch numbers [8–10]. In the Netherlands, 
results from a study in 2014 suggested that brand names 
were not routinely recorded in Dutch clinical practice and 
batch numbers were poorly recorded [10]. The main reported 
bottleneck in the study from the Netherlands was that the 
current EU barcode standards do not support encoding and 
thus automatic recording by means of electronic barcode 
scanning of batch numbers in electronic recording systems. 
This may, at least in part, explain the limited traceability of 
biologics found in ADR reports in the Netherlands. With an 
ever-increasing number of authorised biologics and biosimi-
lars on the market, this topic has become even more relevant 
in recent years and warrants further research. Thus, to assess 
whether these issues apply on a wider scale, we assessed the 
traceability of biologics in the UK.
Hospital pharmacy computer systems in the UK may 
be used only for pharmacy functions such as dispensing, 
labelling and stock control, or they may be integrated with 
hospital-wide systems for electronic recording of pre-
scriptions and administration of medicines. Health profes-
sionals are encouraged to report ADRs to the UK Yellow 
Card Scheme, which is administered by the Medicines and 
Healthcare products Regulatory Agency (MHRA). In hos-
pitals, ADRs reports may be collated by the local medi-
cines information service (a pharmacy subdepartment) 
and transmitted electronically to the MHRA, but health 
professionals may also report to the MHRA directly, inde-
pendent of this system. The aim of the current study (the 
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drug from a predefined list of recombinant biologics were 
included (see Electronic Supplementary Material 2). Non-
electronic reports were excluded, because for these reports 
the original verbatim drug name ‘as reported’ is not feasible 
to extract from the database. ADR reports submitted via 
MAHs and literature reports were also excluded.1 Access to 
anonymised Yellow Card data was provided by the MHRA 
following approval by the Commission on Human Medicines 
(CHM) Pharmacovigilance Expert Advisory Group.
2.2  Data Analysis
2.2.1  Descriptive Analysis
Simple descriptive statistics from the survey data were used 
to summarise the level and method of recording of brand 
name and batch number information in routine clinical prac-
tice. Open ‘free-text’ responses were assessed qualitatively 
by identifying common themes. Pharmacists were asked 
to indicate if they completed the survey for the hospital as 
a whole or for their clinical specialty. For the analysis of 
the hospital survey, the primary unit of analysis was the 
pharmacist.
We assessed the percentage of suspected biologics from 
the electronic ADR reports that contained an identifiable 
brand name (or name of the manufacturer or MAH) from the 
‘as-reported’ suspected drug name. For batch number iden-
tification, entries were assessed to explore whether reported 
batch numbers referred to valid entries (e.g. to exclude false 
entries such as ‘unknown’ or ‘?’). The unit of analysis was 
the suspected biologic. This means that in case two biolog-
ics (from our predefined list) were suspected in one ADR 
report, then this report contributed to the analyses for each 
of the two suspect biologics. Data analysis was stratified by 
year in which the report was received (time trend analysis) 
and by reporter type.
2.2.2  Exploratory Analysis
We assessed a number of possible success factors for facili-
tating the reporting of product information: (1) whether or 
not a biosimilar is approved in a certain product class; (2) 
time to onset of the ADR; and (3) whether biologics required 
(aseptic) compounding before administration to the patient.
Firstly, a subanalysis was performed with regard to brand 
name and batch number traceability for biologics for which 
a biosimilar was available. The year and month of the first 
EU approval of a biosimilar in a product class was used for 
including corresponding ADR reports in this subanalysis.
Secondly, brand name and batch number traceability were 
compared among ADR reports stratified by the time to onset 
of the suspected ADR: ‘< 1 day’, ‘1–7 days’, ‘7–30 days’, 
‘30–180 days’, ‘180–360 days’ and ‘> 360 days’. This analy-
sis was limited to ADR reports for which a single suspected 
drug was reported, the same time to onset was provided for 
all reactions reported for the same case and where at least 
one of the reactions per case was classified as serious,2 as 
time-to-onset data is not routinely captured for non-serious 
reports. ADR reports were excluded from this analysis if no 
time-to-onset information was provided.
Thirdly, batch traceability was compared between ADR 
reports for biologics that do or do not require aseptic com-
pounding prior to administration (e.g. for intravenous for-
mulations) on the basis that good manufacturing practice 
(GMP) standards recommend that batch number details are 
recorded within compounding records [11]. This analysis 
was conducted for the 20 most commonly reported suspect 
biologics from our sample list. Product information within 
the electronic Medicines Compendium (eMC) database was 
used to determine whether compounding was required for 
each of these 20 biologics [12].
3  Results
3.1  Hospital Pharmacist Survey
Of the 174 trusts that were eligible for this study, we col-
lected a total of 61 responses from hospital pharmacists 
representing 40 (23%) NHS Trusts and 43 distinct hospital 
sites. The majority of the survey respondents indicated that 
biologics were always prescribed by brand name (29; 48%) 
or very often (19; 31%). Of the latter group, 13 (68%) indi-
cated that brand name prescribing was more likely where a 
biosimilar (or related product sharing the same International 
Non-Proprietary Name [INN]) is available.
The majority of survey respondents (≥ 79%) reported that 
brand names are routinely recorded for biologics during dis-
pensing and administration in both inpatient and outpatient 
settings (Table 1). Routine batch number recording was 
reported to be performed less frequently, ranging from 40% 
during dispensing to 58% during administration of biologics 
in the inpatient setting and 38% and 57%, respectively, for 
the outpatient setting.
1 Industry reports were excluded as adverse event reports from 
industry-sponsored programmes, such as patient support programmes 
(PSPs), may influence the findings from routine clinical practice in 
the UK, which was the focus of this study.
2 Based on classification of seriousness at source by MHRA accord-
ing to an internal reference list of dictionary terms from the Medical 
Dictionary for Regulatory Activities  (MedDRA®).
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Paper-based recording of product details was more com-
monly reported (≥ 84%) than electronic-based recording 
(≤ 51%) for prescribing and administration of biologics in 
both inpatient and outpatient settings (Table 1). However, for 
dispensing, the majority of the respondents (approximately 
80%) indicated that electronic-based recording was used.
A total of 54 hospital pharmacists responded to the ques-
tion about bottlenecks and potential solutions for ensuring 
adequate brand name and batch number traceability in UK 
clinical practice. Twenty-six (48%) responses indicated that 
the lack of electronic recording systems prevent the rou-
tine recording of batch number information throughout the 
supply chain. Moreover, 17 (31%) responders specifically 
referred to the need for appropriate barcodes and electronic 
systems to facilitate the automatic scanning of batch num-
ber information throughout the supply chain to improve the 
traceability of biologics. Although many hospitals still have 
paper-based recording processes in place to some extent, 
17 (31%) responses indicated that the manual recording of 
every batch number of biologics dispensed and administered 
was considered impractical (i.e. too resource- and time-
intensive), hampered adequate retrieval of product informa-
tion or may be unreliable due to transcription errors or loss 
of information.
3.2  Analysis of Brand Name and Batch Number 
Traceability in Spontaneous Adverse Drug 
Reaction (ADR) Data
A total of 6108 electronic ADR reports were submitted to 
the Yellow Card Scheme for recombinant biologics during 
the study period. However, due to multiple suspect biolog-
ics in some ADR reports, the analysis relates to a total of 
6219 ADR reports at the level of the individual biologic. Of 
these, 2358 (38%) had an identifiable brand name, whereas 
batch numbers were specified for 911 (15%) biologic-level 
reports. The number of electronic ADR reports received by 
the MHRA for biologics steadily increased over the study 
period (Fig. 1). Brand name traceability in electronic ADR 
reports remained constant, whereas batch number traceabil-
ity slightly increased from 11% in 2012 to 17% in 2013.
Product traceability was slightly higher for non-serious 
events, with 43% of the ADR reports having a traceable 
brand name and 17% a traceable batch number compared 
with 33% and 14%, respectively, for serious events.
The majority of the electronic ADR reports for biologics 
were submitted by hospital health professionals, including 
nurses (33% of the reports), doctors (23%) and pharmacists 
(14%) (Table 2). Brand name was most frequently specified 
in reports submitted by patients (76%) and batch numbers 
were most often provided by hospital nurses (20%) and 
patients (19%).
3.3  Exploratory Analyses
For 916 ADR reports, a biosimilar was available in the EU 
for the suspected biologics. Brand name and batch number 
traceability was higher in this subset of reports than overall 
traceability: brand name was specified in 510 of these ADR 
reports (56%), whereas a batch number was provided in 252 
ADR reports (28%).
Time to onset of the reported ADR was available in 1629 
(26%) of the electronic ADR reports for biologics submitted 
to the Yellow Card Scheme. The frequency of batch number 
reporting decreased with increasing time to onset, from 54% 
for ADRs occurring within 24 h of administration to less 
than 3% for ADRs occurring more than a year after admin-
istration (Fig. 2). This effect was observed to a lesser extent 
for brand name identification (Fig. 2).
For the 20 most commonly reported suspect biologics, a 
total of 3165 ADR reports were identified for biologics that 
are supplied in ready-to-use formulations compared with 
1339 ADR reports for biologics that required compound-
ing. For the biologics that required compounding, 354 (26%) 
Table 1  Routine recording 
practices of product details in 
the inpatient and outpatient 
hospital setting
n/a not applicable
a 79% is derived from combined responses indicating ‘always’ and ‘very often’
b Not mutually exclusive as some hospitals use a combination of paper- and electronic-based recording
Recording practice Prescribing Inpatient Outpatient
Dispensing Administering Dispensing Administering
Brand name and batch number recording
 Brand name (%) 79a 91 79 88 80
 Batch number (%) N/a 40 58 38 57
 Number of responses 61 55 48 60 49
Recording type
 Paper (%)b 84 57 85 63 91
 Electronic (%)b 51 82 40 79 34
 Number of responses 61 51 47 56 47
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ADR reports contained an identifiable batch number, which 
was higher than that observed for the 263 (8%) ADR reports 
for biologics supplied in ready-to-use formulations.
4  Discussion
This study shows that product details such as brand name or 
manufacturer were identifiable in less than half of the ADR 
reports submitted for biologics in the UK between 1 Janu-
ary 2009 and 30 September 2017. Furthermore, only 15% 
of the ADR reports included a batch number. The results of 
this study further indicate that the traceability of biologics 
in UK clinical practice is not always ensured, particularly for 
batch numbers. Brand name identification for biologics for 
which a biosimilar has been approved was also limited, with 
only 56% of these ADR reports having an identifiable brand 
name. Although some minor improvements of batch trace-
ability in ADR reporting have been observed over the study 
period, it would appear that the pharmacovigilance legisla-
tion introduced in 2012 to strengthen product identification 
for biologics in ADR reports has not yet achieved its objec-
tive. These findings are in line with an earlier study on the 
traceability of biologics in the Netherlands from 2016 [10].
Fig. 1  Time trend analysis of 
brand and batch traceability in 
electronic adverse drug reaction 
reports between 1 January 2009 
and 30 September 2017. *End 
date 30 September 2017. ADR 
adverse drug reaction
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Table 2  Overview of the six 
reporter types that submitted 
electronic adverse drug reaction 
reports, including stratified 
analysis of brand name and 
batch number specification 
(sorted by total number of 
adverse drug reaction reports 
submitted)
ADR adverse drug reaction
a 74 ADR reports were excluded from this analysis as they involved more than one reporter type
b Percentages are proportions of the column total (N = 6145)
c Percentages represent the proportion of the total number of ADRs reported by the reporter type in the 
respective row
d Reporter type category ‘other’ relates to healthcare professionals not listed in this table such as ‘com-
munity pharmacist’, unspecified healthcare professionals classified as ‘hospital healthcare professional’ or 
where the occupation is not known, classified by the Yellow Card as ‘other healthcare professional’
Reporter type Total ADR  reportsa Number of ADR reports specifying
Brand name Batch number
N %b N %c N %c
Hospital nurse 2016 33 752 37 404 20
Hospital doctor 1437 23 360 25 120 8
Hospital pharmacist 885 14 211 24 91 10
Nurse 443 7 228 51 73 16
Patient 429 7 325 76 81 19
General practitioner 380 6 159 42 19 5
Otherd 555 9 286 52 112 20
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4.1  Hospital Pharmacist Survey
According to the majority of the respondents to the sur-
vey, brand names are routinely recorded during the dispens-
ing process (Table 1). The survey also showed that routine 
batch numbers recording occurs less frequently during rou-
tine clinical practice. With regard to recording practices 
throughout the hospital supply chain, it was indicated by 
the respondents that batch number recording is highest at 
the time of administration. A reason for this could be the 
prevalent use of paper-based recording for administration 
that facilitates the manual entry of batch numbers or the 
use of peel-off stickers (‘flag labels’) containing the batch 
number. It was indicated that electronic-based recording was 
primarily used during dispensing, which may hamper the 
routine recording of batch numbers because the current EU 
barcode standards do not support automatic recording of 
batch numbers in electronic systems [13–15]. The absence 
of adequate recording and tracing of batch numbers in UK 
clinical practice as well as integrated IT systems, for exam-
ple coupled with the independent Yellow Card Scheme, may 
contribute to the limited traceability of batch numbers in 
ADR reporting.
4.2  Product Traceability in ADR Reports
The ADR data analysis showed that the pharmacovigilance 
legislation of 2012 did not have a marked or sustained effect 
on brand name and batch number traceability for biolog-
ics after its implementation in UK law, even after a num-
ber of years. Although the results show a slight increase 
of batch number traceability initially after 2012, from 11 
to 17% in 2013 (Fig. 1), this could also be explained by 
the automatic batch number prompts that were introduced 
by the MHRA in the online reporting form of the Yellow 
Card Scheme in 2013 as a result of the legislation (MHRA, 
personal communication, 2019). Brand name traceability 
was slightly increased for biologics for which biosimilars 
were available. Besides an increased awareness of the leg-
islative requirement to specify the brand where biosimilars 
are available, e.g. by NHS guidance on biosimilars [16], this 
effect can be further amplified by the fact that if only one 
brand is available, the reporter may not consider it necessary 
to specify a brand when submitting an ADR report. None-
theless, with only 56% of the ADR reports for biologics for 
which a biosimilar has been approved having an identifiable 
brand, traceability needs to be further improved to ensure 
timely detection of product-specific safety signals.
We observed that patients were most likely to include a 
brand name in ADR reports (Table 2). This finding is sup-
ported by other EU studies [8]. Batch number inclusion was 
highest for hospital nurses. A reason for this can be found 
in the findings from the survey indicating that batch number 
recording is highest during administration (Table 1). This 
could indicate that the availability of batch number informa-
tion at the point of administration allows for hospital nurses 
to have easier access to this information and thus it is more 
likely to be included in ADR reports submitted by hospital 
nurses.
The limited traceability of batch numbers in ADR reports 
due to shortcomings in recording and tracing detailed prod-
uct information in clinical practice is further supported by 
the time-to-onset analysis, which shows that batch numbers 
(and to a lesser extent brand names) are more likely to be 
included in ADR reports when the time to onset is short, e.g. 
within 1 day (i.e. acute onset), and consistently decreases 
with increasing time to onset. This can be explained by the 
fact that with an acute onset, the medicinal product pack-
age or container on which the batch number information 
is printed may still be present and therefore accessible to 
retrieve the batch numbers of the biologic that was admin-
istered. Obviously, retrieving the batch number from the 
Fig. 2  Overview of the correla-
tion between time to onset and 
likelihood that a brand name or 
batch number was included in 
an adverse drug reaction report. 
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product package will not be possible once the package has 
been discarded. However, it is also known that batch-related 
ADRs, particularly those leading to immune-mediated reac-
tions, have a short latency period between administration 
and manifestation of the ADR. This could contribute to a 
greater alertness by the reporter to include the batch number 
in such cases and, vice versa, reduce the perceived relevance 
of reporting a batch number for ADRs occurring a longer 
period after administration.
The assumption that the adequate recording (and there-
fore availability) of product information is directly related 
to inclusion of these details in ADR reports is further sup-
ported by our subanalysis comparing biologics requiring 
aseptic compounding, for which batch number recording in 
aseptic preparation worksheets is a mandatory procedure as 
part of GMP requirements, with biologics that can readily 
be distributed to the patient. The results indicate that batch 
numbers are more likely included in ADR reports for biolog-
ics that require aseptic compounding than for biologics that 
do not require compounding. This suggests that batch num-
bers are more likely to be traceable in ADR reports in situ-
ations where these details are more readily accessible (e.g. 
if routinely recorded) in clinical practice.
4.3  Comparison to Other Studies
Our findings here support our earlier findings in the Neth-
erlands that the limited traceability of biologics in ADR 
reports may be primarily caused by shortcomings in the 
adequate recording and tracing of this information in clini-
cal practice [10]. The finding that the new pharmacovigi-
lance legislation from 2012 has not yet made any substan-
tial improvement with regard to traceability, in particular 
for batch numbers, is supported in the literature. We found 
poor batch number traceability (5%) in the Netherlands 
[10], while another recent study in EudraVigilance esti-
mated batch traceability at 20.5% [17]. However, it needs 
to be pointed out that the study in EudraVigilance by Ver-
meer et al. [17] included blood products for which standard 
protocols for batch number recording have existed for over 
25 years, which may have skewed the analysis towards a 
more positive result for batch number traceability [15, 18].
Discrepancies exist between studies with regard to brand 
name traceability in the EU. The recent study in EudraV-
igilance indicated that brand name traceability was 96% for 
biologics that share the same INN (e.g. if a related biologic 
or biosimilar is approved) [17]. These findings are, however, 
not supported in the current UK study nor in our earlier 
study in the Netherlands. The discrepancies in the findings 
by other studies that showed a higher traceability of brand 
names for biologics may be due to inclusion of ADR reports 
from MAHs. ADR reports originating from MAHs may 
account for a large portion of total ADR reports found in 
databases. It has been shown in the scientific literature that 
many reported adverse events are provided by industry-spon-
sored programmes, such as PSPs [19, 20]. In these cases, 
brand names are logically known at the time of reporting.
4.4  Limitations
A number of limitations need to be taken into account when 
interpreting the results of this study. First, the known limita-
tions that apply to surveys in general are also applicable to 
this study, such as response variability and response rate. 
This survey tried to capture a very diverse environment with 
a limited set of simple questions. We believe that the total 
of 61 responses provided a sufficiently robust overview of 
the recording practices in the UK hospital setting to support 
the conclusions from this study. As the survey requested 
information on recording of biologics in general, it is pos-
sible that it did not fully capture variation in recording prac-
tices that may occur for different products. For example, 
recording of the brand name may occur when a biosimilar 
is available and only a non-proprietary name is recorded if 
no biosimilar is on the market. However, we believe that this 
does not impact the overall conclusions of the study. Since 
this was a cross-sectional survey, pharmacists’ responses at 
a particular point in time may not reflect the much greater 
time span covered by the second analysis of electronic ADR 
reports submitted to the UK national spontaneous reporting 
database. Thus, any indirect correlation between recording 
practices and their effect on traceability within ADR reports 
should be made with caution.
The use of the ‘as-reported’ drug name field to measure 
brand name recording in ADR reports can have minor impli-
cations since this information could have been updated, e.g. 
during follow-up of spontaneous cases. Such updates were 
not identifiable in the analysis dataset. However, this was 
considered to have no meaningful impact on the broader 
interpretation of the results of the ADR data analysis. For 
the subanalysis of the brand and batch identification in 
ADR reports for biologics for which a biosimilar has been 
approved, we used the date of approval by the European 
Medicines Agency (EMA). However, this may not reflect 
the actual date of biosimilar uptake in UK clinical prac-
tice, which may slightly influence the interpretation of this 
analysis.
4.5  Relevance and Recommendations
With clinical healthcare settings in the UK moving from 
paper-based recording to electronic-based recording, UK 
hospitals should consider addressing the current shortcom-
ings of appropriate routine recording and tracing of dynamic 
product information such as batch numbers (and expiry 
dates). Furthermore, UK hospitals should address how 
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ADRs that occur within their healthcare settings are cap-
tured fully and transmitted to the MHRA for patient safety 
analysis and signal detection. To this end, the MHRA has 
developed an electronic information standard for clinical IT 
system suppliers to integrate ADR reporting into their sys-
tems, which includes the appropriate fields required [21]. 
However, until the encoding of batch numbers in barcodes 
printed on the single unit dose is ensured to facilitate bar-
code scanning at the administration site, challenges will 
remain with implementing electronic-based routine record-
ing of dynamic product information throughout the entire 
supply chain. The recently established Falsified Medicines 
Directive (FMD), a piece of legislation that aims to prevent 
the entry of counterfeit medicinal products into the supply 
chain, could at least partially be deployed for improving the 
traceability of biologics in the transition towards more rou-
tine electronic-based recording in UK healthcare practice 
[14, 22, 23].
The transition towards electronic-based recording and 
in tandem addressing of current limitations of traceability 
should be approached from the broader public health per-
spective to find cost-effective solutions to improve the trace-
ability. Other initiatives, such as the FMD or ‘Scan4Safety’ 
for the reduction of medication errors by implementing bar-
code medication verification technology at the site of admin-
istration, could be aligned in a joint effort to improve the 
traceability of biologics in the wider framework of ultimate 
patient care and supply chain efficiency [24]. Nonetheless, 
from a policy perspective, more efforts are needed at the 
national level to support automated recording of product 
information with electronic barcode scanning throughout 
the supply chain. Furthermore, more awareness and addi-
tional education about the importance of the traceability of 
biologics, such as the MHRA’s Drug Safety Updates [25, 
26], ADR e-learning modules [27] and a strengthened dia-
logue between regulators and healthcare professionals via 
the National Medication Safety Network, could contribute to 
improving traceability in ADR reports and ultimately guar-
antee adequate product and batch identification for optimal 
public health protection. This study tries to contribute to 
this.
5  Conclusion
Brand name and batch number traceability are generally 
low for biologics in UK ADR reports, being 38% and 15%, 
respectively. Improvements of batch number traceability 
have been observed after the implementation of the pharma-
covigilance legislation in 2012; however, no major improve-
ments were identified with regard to brand name traceability. 
Shortcomings in the systematic recording of product details 
in UK clinical practice, particularly for batch numbers, may 
contribute to the limited traceability of this information 
in ADR reporting. Pharmacovigilance legislation has not 
resulted in a significant improvement in the traceability of 
biologics. This study tries to contribute to increasing the 
understanding that the legislation can only be effective for 
these products if a robust traceability of product information 
in clinical practice is ensured. Improvements of recording 
and tracing of product details throughout the entire sup-
ply chain are therefore needed and should be aligned with 
other drug safety objectives. Education and training on the 
importance of traceability for biologics in ADR reporting 
can further support improving the traceability. These efforts 
will eventually help to build a robust pharmacovigilance sys-
tem that allows for the timely identification of any product-
related issues.
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